06660 AIM VACCINE
- 8.880
- +0.160+1.83%
AIM VACCINE News
艾美疫苗：2023年度報告
Would AIM Vaccine (HKG:6660) Be Better Off With Less Debt?
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of permanent loss is the risk I worry about... and every practical investor I know wor
Emmy Vaccines received controlling shareholder Zhou Yan to continue to increase his shareholding
Le Méridien Vaccine (06660) issued an announcement. The board of directors of the company received a notice from Zhou Yan (Chairman of the Board of Directors, Executive Director, CEO and controlling shareholder of the Company) that Zhou Yan will continue to further increase the company's H shares (“this increase”) through the open market from January 12, 2024 to April 15, 2024. From November 14, 2023 to April 15, 2024, Zhou Yan has continued to increase her H shares in the company with a total of HK$10,420,212.00 through the open market, and it is not ruled out that she will continue to increase her shares in due course. As of the date of this announcement
Gelonghui Announcement Selection (HK Stock) | Ideal Automobile-W (02015.HK) Officially Launches Family 5-Seater Luxury SUV - Ideal L6
Ideal Automobile-W (02015.HK) officially released the family's five-seater luxury SUV - Ideal L6
Le Méridien Vaccine (06660.HK) Voluntary Announcement: Controlling Shareholder Continues to Further Increase H Shares
Gelonghui, April 18, 丨 Le Méridien Vaccine (06660.HK) announced that the company's board of directors received a notice from Zhou Yan (Chairman of the Board, Executive Director, CEO and controlling shareholder of the company). Zhou Yan continued to further increase the company's H shares through the open market from January 22, 2024 to April 18, 2024. From November 14, 2023 to April 18, 2024, Zhou Yan has continued to increase her H shares in the company through the open market with total capital of HK$10,420,212.00, and it is not ruled out that she will continue to increase her shares in due course. As of this announcement
Aim Vaccine Submits Pre-Applications for Clinical Trials for Two Vaccines; Shares Up 3%
Aim Vaccine (HKG:6660) submitted pre-applications for clinical trials for two vaccines on Thursday, according to two separate Hong Kong bourse filings on the same day. These include the quadrivalent i
Aim Vaccine's Loss Quadruples in 2023 as Revenue Slips 6%; Shares Up 3%
Aim Vaccine (HKG:6660) booked an attributable loss of 1.3 billion yuan in 2023, up 307.1% from 319.6 million yuan the prior year, according to a Thursday Hong Kong bourse filing. Loss per share for th
Aimei Vaccine (06660) has submitted a pre-application for clinical trials of Haemophilus influenzae type b (Hib) conjugate vaccine
The Le Méridien vaccine (06660) was announced. The group submitted Haemophilus influenzae type b (H...
The Le Méridien vaccine (06660) has entered a major year of intensive reporting, and the mRNA technology platform lays out multiple popular vaccines
The Zhitong Finance App learned that on March 28, Emmy Vaccine (06660) released the 2023 results and several major new product development announcements. The data...
AIM VACCINE: ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED DECEMBER 31, 2023
Another major iterative upgrade of the rabies vaccine submitted for clinical trials, and the Le Méridien vaccine (06660) has entered a major reporting year
The Zhitong Finance App learned that the Emmy Vaccine (06660) announced on the evening of the 26th that the company has recently submitted a pre-clinical trial application for a novel, high-cost human diploid rabies vaccine. This is another major milestone in Emmy Vaccine's promotion of mad vaccine development according to the established strategy after the layout of the iterative upgrade series of rabies vaccines was completed at the beginning of this month. Major manufacturers of Mad Miao are making efforts to lead the global industry's in-depth technological iterative upgrading. According to the announcement, Le Méridien's novel process is an efficient and affordable human diploid rabies vaccine, which has many innovative points. It was the first to break through the traditional technical bottleneck of the low virus titer and low yield of this process, and carried it out in the purification process
Le Méridien Vaccine (06660): Novel Process and Highly Effective Human Diploid Rabies Vaccine Submits Pre-Application for Clinical Trials
Le Méridien Vaccine (06660) announced that on March 24, 2024, the group submitted a novel process with high cost efficiency 2...
One AIM Vaccine Insider Raised Stake By 27% In Previous Year
From what we can see, insiders were net buyers in AIM Vaccine Co., Ltd.'s (HKG:6660 ) during the past 12 months. That is, insiders acquired the stock in greater numbers than they sold it. While ins
Aimei Vaccine (06660.HK) held a board meeting on March 27 to consider and approve annual results
Glonghui March 15 | Le Méridien Vaccine (06660.HK) announced that the board of directors meeting will be held on March 27, 2024 (Wednesday) to consider and approve (among other things) the annual results and announcements of the company and its subsidiaries for the year ended 31 December 2023, consider recommending payment of a final dividend (if any), and deal with other matters.
AIM VACCINE: NOTICE OF BOARD MEETING
Changes in Hong Kong stocks | Le Méridien vaccine (06660) is now up more than 6%. The three major iterative vaccines were declared for marketing during the year, and research and development work is progressing comprehensively
The Le Méridien vaccine (06660) is now up more than 6%. As of press release, it has risen 6.03% to HK$7.91, with a turnover of HK$11.654 million.
AIM Vaccine Files Pre-Application for Marketing Registration of Its Pneumonia Vaccine
AIM Vaccine (HKG:06660) submitted its pre-application for marketing registration for its 13-valent pneumonia conjugate vaccine, a Friday bourse filing said. The company plans to complete the marketing
AIM Vaccine Expediting Development of Iterative Rabies Series Vaccines; Shares Drop 4%
AIM Vaccine (HKG:6660) accelerated the development of its iterative rabies series vaccines, according to a Monday bourse filing. The vaccine producer already completed the phase 3 trials of its iterat
AIM Vaccine Expects Wider Loss in 2023; Shares Slide 4%
AIM Vaccine (HKG:6660) expects its attributable net loss to have widened to between 1.25 billion yuan and 1.38 billion yuan in 2023 from 320 million yuan in 2022, a Monday filing said. The higher loss
AIM Vaccine Starts Advances Trial of Meningococcal Vaccine in China; Shares Fall 4%
AIM Vaccine (HKG:6660) started phase 2 trials of its tetravalent meningococcal conjugate vaccine in Yunnan Province, China, a Monday filing said. The company already completed the construction of its
Analysis
Price Target
No Data
